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Introduction: Afatinib is an effective first-line treatment in patients 
with epidermal growth factor receptor (EGFR)-mutated non–small-cell 
lung cancer (NSCLC) and has shown activity in patients progressing on 
EGFR-tyrosine kinase inhibitors (TKIs). First-line afatinib is also effec-
tive in patients with central nervous system (CNS) metastasis. Here we 
report on outcomes of pretreated NSCLC patients with CNS metastasis 
who received afatinib within a compassionate use program.
Methods: Patients with NSCLC progressing after at least one line of 
chemotherapy and one line of EGFR-TKI treatment received afatinib. 
Medical history, patient demographics, EGFR mutational status, and 
adverse events including tumor progression were documented.
Results: From 2010 to 2013, 573 patients were enrolled and 541 
treated with afatinib. One hundred patients (66% female; median age, 
60 years) had brain metastases and/or leptomeningeal disease with 
74% having documented EGFR mutation. Median time to treatment 
failure for patients with CNS metastasis was 3.6 months, and did not 
differ from a matched group of 100 patients without CNS metasta-
sis. Thirty-five percent (11 of 31) of evaluable patients had a cere-
bral response, five (16%) responded exclusively in brain. Response 
duration (range) was 120 (21–395) days. Sixty-six percent (21 of 32) 
of patients had cerebral disease control on afatinib. Data from one 
patient with an impressive response showed an afatinib concentration 
in the cerebrospinal fluid of nearly 1 nMol.
Conclusion: Afatinib appears to penetrate into the CNS with con-
centrations high enough to have clinical effect on CNS metasta-
ses. Afatinib may therefore be an effective treatment for heavily 
pretreated patients with EGFR-mutated or EGFR–TKI-sensitive 
NSCLC and CNS metastasis.
Key Words: Afatinib, ErbB family blocker, Central nervous system 
metastasis, Non–small-cell lung cancer, Compassionate use program.
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Non–small-cell lung cancer (NSCLC) is the leading cause of cancer-related death in many countries.1 The progno-
sis for advanced-stage disease has improved in the last two 
decades; however, with a 5-year survival rate of only approxi-
mately 15% the treatment of this disease remains a clinical 
challenge.1 In a subset of lung adenocarcinoma, somatic muta-
tions of the gene encoding the epidermal growth factor recep-
tor (EGFR), in particular those clustering in exons 19 and 
21, result in the expression of a structurally altered receptor 
and oncogenic activation of signaling pathways. Mutations in 
the EGFR gene define tumors in which cell survival is driven 
by and dependent on EGFR pathway signaling.2 EGFR-gene 
mutations are found in 10 to 15% of white patients and up to 
60% of Asian patients, especially never-smokers and patients 
with adenocarcinoma. In addition, an over expression of 
EGFR has been detected in 40 to 80% of NSCLC patients.3–5
Clinical trials have demonstrated that first-line treat-
ment with reversible EGFR tyrosine kinase inhibitors (TKIs), 
such as gefitinib or erlotinib, leads to improvement in pro-
gression-free survival (PFS) when compared with chemother-
apy.6–10 However, despite good initial responses, patients with 
EGFR-mutated NSCLC go on to develop TKI resistance and 
disease progression after a median duration of 8 to 10 months 
on therapy.11
Small-molecule inhibitors with higher binding affin-
ity and a broader target profile may improve treatment effi-
cacy and delay the development of treatment resistance in 
EGFR-mutated NSCLC.12–14 Afatinib is an orally available, 
irreversible ErbB family (EGFR/ErbB1, human epidermal 
growth factor receptor-2 [HER2; ErbB2], and ErbB4) blocker 
approved in the European Union, United States, and several 
Asian and Latin American countries for TKI-naive patients 
with EGFR-mutated NSCLC.15,16 In contrast to the reversible 
EGFR-TKIs erlotinib and gefitinib, afatinib has been shown 
to bind covalently to the ErbB receptor in vitro, irreversibly 
blocking signaling and leading to sustained antimitogenic 
activity. Two large randomized clinical trials (LUX-Lung 3 
and LUX-Lung 6) have demonstrated that afatinib prolongs 
PFS to an average of 13.6 months in patients with EGFR exon 
19 deletion or exon 21 L858R mutation in the first-line setting. 
In addition, the LUX-Lung 1 trial in patients pretreated with 
reversible TKIs and platinum-based chemotherapy showed a 
median PFS of 3.3 months with afatinib monotherapy com-
pared with 1.1 months for patients treated with placebo plus 
best supportive care. The LUX-Lung trials allowed enrolment 
of patients with stable brain metastases (BM). A recently 
reported analysis of 35 patients with BM from LUX-Lung 3 
treated first line with either afatinib or cisplatin/pemetrexed 
showed a median PFS of 11.1 months on afatinib compared 
with 5.4 months for those treated with chemotherapy (hazard 
ratio [HR], 0.52; p = 0.13). This finding is of high clinical rele-
vance as the central nervous system (CNS) is a common site of 
metastatic spread in NSCLC, with BM and/or leptomeningeal 
disease (LD) affecting 21 to 64% of patients during the course 
of disease,17–20 and 10 to 20% of patients at the time of first 
diagnosis.21 CNS metastasis limits the prognosis of patients 
with NSCLC,17 with a median survival of only 1 month with-
out treatment,22 2 months with glucocorticoid therapy, and 2 
to 5 months with whole brain radiation therapy.23–27 In addition 
to limiting survival, CNS metastases often cause neurological 
symptoms and a decrease in quality of life.28
The introduction of targeted therapies such as EGFR-
TKIs has broadened the therapeutic options available to 
NSCLC patients with activating EGFR mutations.29,30 EGFR-
TKIs are now recommended for first-line treatment of patients 
with EGFR mutation-positive NSCLC.12 However, data on the 
efficacy and cerebral bioavailability of EGFR-TKIs in patients 
with CNS metastasis remain limited.
The afatinib compassionate use program (CUP) was 
initiated in May 2010 after availability of the results of the 
LUX-Lung 1 trial,31,32 and was intended to provide access to 
afatinib for patients progressing on erlotinib or gefitinib. Here 
we present an analysis of treatment efficacy in patients with 
BM who were treated with afatinib during this CUP.
MATERIALS AND METHODS
Afatinib CUP
Participation in the afatinib CUP was available to 
patients with advanced NSCLC who were ineligible to par-
ticipate in another actively accruing afatinib trial and who 
had failed at least one line of platinum-based chemotherapy 
and progressed following at least 24 weeks on erlotinib or 
gefitinib. Additional inclusion criteria were age 18 years or 
older, absence of an established treatment option, and written 
informed consent. The intention of this CUP was to provide 
controlled preregistration access to afatinib for patients with 
life-threatening diseases and no other treatment option.
Afatinib was given as a continuous oral treatment at 
a starting dose of 50 mg/day. Lower starting doses of 40 or 
30 mg were allowed at the discretion of the treating physician. 
Dose modifications (10-mg steps, maximum dose: 50 mg/
day, minimum dose: 30 mg/day) were allowed. One treatment 
cycle was defined as 30 days. The protocol was approved by 
the responsible ethics committee (Medical Board of the State 
Rhineland-Palatine, 837.105.10[7114]), and the required 
regulatory authorities (BfArM and regional authorities) were 
informed. As required by regulations, the CUP was stopped 
with the availability of afatinib (GIOTRIF®) on the market.
Within the CUP participating physicians were asked 
to provide a pseudonymized clinical data set for each patient 
including gender, age, comorbidities, disease stage, prior 
therapies, and EGFR mutation status. This information was 
used to confirm patient eligibility for the CUP. Reporting of 
adverse events including tumor progression was mandatory. 
Physicians with patients known to have CNS involvement 
were approached to collect further data on BM, LD, radiation, 
and outcome.
Pharmacokinetic Analyses
One patient consented to pharmacokinetic analyses 
of blood and cerebral spinal fluid (CSF) samples. Blood 
samples were collected in ethylenediaminetetraacetic acid 
drawing tubes. Validated bioanalytical assays for the deter-
mination of afatinib in human ethylenediaminetetraacetic 
acid plasma and in human CSF (with 1% citric acid added 
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to prevent adsorption loss) were used for sample analysis.33,34 
Afatinib was analyzed by high-performance liquid chroma-
tography coupled to tandem mass spectrometry (HPLC-MS/
MS) using isotope-labeled afatinib as internal standard. Solid-
phase extraction was performed on plasma samples before 
the extract was injected onto the HPLC-MS/MS instrument. 
CSF samples were injected directly without a prior extraction 
step. Chromatographic and mass spectrometric conditions 
were identical for both matrices. Samples were subjected to 
chromatography on a reversed-phase analytical HPLC col-
umn with gradient elution. Afatinib and internal standard 
were detected by MS/MS using electrospray ionization in the 
positive mode. Calibration ranges were linear from 0.500 to 
250 ng/ml for plasma and from 0.100 to 20.0 ng/ml for CSF, 
respectively. The analyses met all acceptance criteria.
Matched Patients
Each patient with CNS metastasis was matched with 
one patient from the CUP without CNS metastasis for age, 
gender, histology, mutational subgroup, median treatment 
duration with reversible EGFR-TKI, and treatment line.
Statistical Analyses
Descriptive analysis was performed for patient demo-
graphics. Time to treatment failure (TTF) was defined from 
start of afatinib treatment (if not reported it was calculated as 
7 days after shipment) to end of treatment stop (if not reported 
the date of the last order was used). Systemic response was 
defined as a response of both the primary tumor and metas-
tasis outside the CNS. General response was defined as a 
response of the primary tumor and of all metastases including 
those in the CNS. The database was locked on December 31, 
2013 and patients on treatment were censored. Survival curves 
were estimated using the Kaplan–Meier method for TTF and 
overall survival. A Cox model was applied to estimate HRs 
and 95% confidence intervals with significance set at p value 
less than 0.05. Analyses were undertaken using MedCalc 
for Windows, version 12.1.4.0 (MedCalc Software, Ostend, 
Belgium). Patients who received less than 2 months of afatinib 
due to progressive disease (PD) or death were classified “PD” 
as best response, whereas patients receiving treatment for a 
period of more than 4 months were classified “stable disease” 
(SD) as best response if not reported differently.
RESULTS
Between May 2010 and December 2013, 573 patients 
were included in the CUP and 541 were treated with afa-
tinib.35 One hundred patients (66% female; median age, 60 
years; range, 31–78 years) were reported to have either BM or 
LD (Table 1). Of those 97% had adenocarcinoma, 74% were 
reported to have an EGFR mutation confirmed by molecular 
pathology, and 77% of the reported EGFR mutations were 
exon 19 deletions or exon 21 L858R mutations. Seventy-two 
percent of patients with CNS metastasis also had bone metas-
tasis. The patients were matched for analyses with 100 compa-
rable NSCLC patients without CNS metastasis.
All patients in the CUP were pretreated with chemother-
apy and erlotinib/gefitinib; first-line therapy was a platinum 
doublet in the majority (64%), and erlotinib (13%) and gefi-
tinib (22%) in a subset (Table 2). The most common second-
line treatments were erlotinib (38%) and gefitinib (22%), and 
38% of patients received erlotinib in third-line. The majority 
of patients were enrolled in the CUP for third-line or fourth-
line treatment, but individual patients with up to 12 prior treat-
ment lines were also registered.
The CUP protocol suggested a starting dose of 50 mg 
afatinib daily; however, this dose could be modified by the 
treating physician depending on side effects during prior 
EGFR-TKI treatment and the patient’s general performance 
status. Accordingly, starting doses were 50 mg (n = 71), 40 mg 
(n = 25), and 30 mg (n = 4). Dose reductions from 50 to 40 mg 
were carried out in 51% of patients, and from 40 to 30 mg 
in 80%. The main reasons for dose reductions were diarrhea 
(70% of dose reductions) and skin rash (24%).
Efficacy of Afatinib in Pretreated 
Patients with CNS Metastases
We analyzed patients’ previous response to treatment 
with erlotinib or gefitinib before their inclusion in the CUP. 
Patients with CNS metastases had been treated with erlotinib 
or gefitinib for a median of 9 months (range, 1–36 months). 
Data on general best response were available for 68 of these 
patients: 18% (12 of 68) had experienced a partial remis-
sion (PR), 53% (36 of 68) had SD, and 29% (20 of 68) had 
PD. Detailed information about the first diagnosis of CNS 
metastases was available for a subset of patients. Twenty-
four percent (11 of 46) were reported to have developed CNS 
metastases after treatment with reversible TKIs. CNS metasta-
ses were first detected by computed tomography (CT) in 29%, 
by positron emission tomography-CT in 4%, and by mag-
netic resonance imaging in 67%. One patient had LD without 
further brain metastasis, 28% (10 of 36) had a solitary brain 
metastasis, 22% (8 of 36) had 2 to 5 brain metastases, and 
47% (17 of 36) patients had more than five metastases in the 
CNS. Twenty-one percent (6 of 29) of patients had LD. Sixty-
nine percent of patients were symptomatic from their CNS 
metastases, and 88% were treated with cranial radiation prior 
to afatinib therapy (36 of 41, median dose 30 Gy).
The clinical efficacy of afatinib was determined by 
calculating the TTF for each patient. TTF under afatinib in 
patients with CNS metastases was 3.6 months and did not dif-
fer from the TTF in matched patients without CNS metasta-
ses (HR, 1.16; 95% confidence interval, 0.83–1.62; p = 0.52; 
Fig. 1). TTF for patients with known EGFR mutations (n = 72) 
was 4.0 months, for patients with unknown mutational status 
(n = 20) 3.6 months, and for wild-type patients (n = 8) 1.3 
months.
Most patients with CNS metastases benefited from 
treatment with afatinib. Forty-two percent (13 of 31) of the 
evaluable patients experienced a PR on afatinib, 39% (12 of 
31) had SD, and only 19% (6 of 31) had PD (Fig. 2). The 
disease control duration was 4 months (range, 1–13 months). 
Nineteen percent (6 of 31) had a general response (defined 
as systemic and CNS response), 16% (5 of 31) had a cere-
bral response only, and 13% (4 of 31) had a systemic response 
only. Therefore, the overall rate of cerebral response to 
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treatment with afatinib was 35%. Sixty-six percent (21 of 32) 
of patients had CNS disease control on afatinib, whereas 23% 
(8 of 35) had an isolated cerebral progression during treatment 
(Fig. 3; please note that data on recurrence pattern were not 
always fully reported). Afatinib was discontinued in 39% of 
patients due to progression, in 17% due to death, in 7% due to 
side effects, and in 3% due to patient request. Twelve percent 
of patients were lost to follow-up, and 22% of the patients 
remained on treatment with afatinib at the end of the CUP. 
Typical adverse events, including diarrhea, skin/mucosal tox-
icity, nausea/vomiting, and fatigue, were observed as expected 
based on previous experiences with afatinib.31,32 The overall 
survival (OS) was 9.8 months (31% maturity). There were no 
unexpected safety signals.35
Two cases of patients with CNS metastasis are of great 
interest and shall be described here in detail.
Case Report 1
In June 2011, a 59-year-old never-smoking woman 
was diagnosed with stage IV adenocarcinoma of the lung 
(cT2b pN2 M1a, PLE) and proof of an L858R exon 21 muta-
tion of the EGFR gene. First-line gefitinib treatment led to 
TABLE 1.  Characteristics of the Patients with and without CNS Metastasis and of the Matched Group without CNS Metastasis
Patients with CNS Metastasis 
(N = 100)
Matched Patients without CNS 
Metastasis (N = 100)
Patients without Known CNS 
Metastasis (N = 451)
Gender, n (%)
  Female 66 (66) 67 (67) 297 (66)
  Male 34 (34) 33 (33) 154 (34)
Median age, year (range) 60 (31–78) 57(37–84) 66 (28–89)
Histology, n (%)
  Adenocarcinoma 97 (97) 97 (97) 345 (76)
  SCC 3 (3) 3 (3) 27 (6)
  BAC 0 (0) 0 (0) 20 (4)
  LCC 0 (0) 0 (0) 10 (2)
  Unknown 0 (0) 0 (0) 49 (11)
EGFR mutational status, n (%)
  Exon 18 4 (4) 4 (4) 8 (2)
  Exon 19 32 (32) 34 (34) 137 (31)
  Exon 21 25 (25) 23 (23) 64 (15)
  Exon 19 and T790M 3 (3) 2 (2) 14 (3)
  Exon 21 and T790M 1 (1) 2 (2) 10 (2)
  Exon 20 2 (2) 1 (1) 4 (1)
  HER2 1 (1) 0 (0) 0 (0)
  EGFRM 4 (4) 5 (5) 31 (7)
  Wildtype 8 (8) 8 (8) 55 (13)
  Unknown 20 (20) 21 (21) 130 (30)
Treatment history (months)
  Median treatment duration with erlotinib (range) 9 (9–61) 12 (1–51) 11 (1–60)
  Median treatment duration with gefitinib (range) 8 (5–33) 8 (1–19) 10 (1–112)
  Median time from diagnosis to afatinib (range) 23 (5–65) 23 (4–138) 26 (3–149)
Afatinib treatment line, n (%)
  Median 3 3 4
  2 5 (5) 6 (6) 25 (6)
  3 48 (48) 49 (49) 174 (39)
  4 26 (26) 27 (27) 130 (29)
  5 11 (11) 11 (11) 51 (11)
  6 3 (3) 2 (2) 26 (6)
  7 3 (3) 3 (3) 10 (2)
  8 2 (2) 0 (0) 1 (0)
  9 0 (0) 1 (1) 2 (0)
  ≥10 2 (2) 1 (1) 2 (0)
  Unknown 0 (0) 0 (0) 31 (7)
BAC, bronchioloalveolar carcinoma; CNS, central nervous system; EGFR, epidermal growth factor receptor; EGFRM, EGFR mutation; LCC, large cell carcinoma; SCC, squamous 
cell carcinoma.
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a partial remission for a duration of 9 months and was fol-
lowed by second-line therapy with two cycles of pemetrexed 
500 mg/m2. In June 2012, the patient developed symptomatic 
peritoneal carcinomatosis, an ovarian mass, pulmonary, and 
bone metastases. A rebiopsy from the peritoneum showed 
10 to 20% L858R/T790M-positive tumor cells. Subsequent 
therapy with four cycles of cisplatin (40 mg/m2, d1+8) and 
gemcitabine (1000 mg/m2, d1+8, q d22) resulted in a minor 
response for a further 6 months. She then developed lepto-
meningeosis carcinomatosa (cytological confirmation in the 
spinal fluid) and was hospitalized with an Eastern Cooperative 
Oncology Group performance status of 3/4. The patient sub-
sequently received a fourth-line therapy with afatinib 50 mg/
day. After a few days the neurological symptoms regressed, 
the vomiting stopped, and the Eastern Cooperative Oncology 
Group performance status dramatically improved to 1/2 when 
the patient was discharged. Furthermore, the lung metastases 
were regressive with extension of a partial response accord-
ing to Response Evaluation Criteria in Solid Tumors 1.1. One 
month after beginning afatinib therapy, there was no evidence 
of tumor cells in the spinal fluid.
The plasma concentration of afatinib 3 hours after 
administration was 66.7 ng/ml BIBW 2992 base (BS; the 
free base of afatinib). The concentration of CSF 3 hours after 
administration was 0.464 ng/ml BIBW 2992 BS, which is 
equivalent to a concentration of approximately 1 nMol afa-
tinib in the CSF (Fig. 4).
Then the patient developed diarrhea and elevated liver 
transaminases (2–5 times upper limit of normal). The course 
of disease was complicated by acute renal failure after con-
trast media (for CT) in conjunction with moderate diarrhea. 
The dosage was reduced to 40 mg afatinib. In May 2013 (5 
months after starting afatinib), the patient died of sepsis fol-
lowing an infection of the port-catheter without evidence of 
progression of the leptomeningeosis carcinomatosa.
Case Report 2
In February 2007, a 61-year-old male smoker was first 
diagnosed with stage IV adenocarcinoma of the lung and two 
cerebral metastases (pT4 pN1 M1b). After a bilobectomy 
TABLE 2.  Pretreatment of the Patient Group with CNS Metastasis
First Line Second Line Third Line Fourth Line
N = 100 (100%) N = 94 (94%) N = 45 (45%) N = 16 (16%)
Chemotherapy, n (%) 65 (65) 37 (39) 24 (53) 14 (88)
  Platinum doublet 64 (64) 20 (21) 10 (22) 2 (13)
  Pemetrexed mono 6 (6) 6 (13) 3 (19)
  Docetaxel mono 3 (3) 7 (16) 3 (19)
  Gemcitabine mono 4 (25)
  Etoposide, Vinorelbine 4 (4) 1 (6)
  Others 1 (1) 4 (4) 1 (2) 1 (6)
EGFR-targeting therapy, n (%) 35 (35) 57 (61) 21 (47) 2 (12)
  Erlotinib 13 (13) 36 (38) 17 (38) 1 (6)
  Gefitinib 22 (22) 21 (22) 4 (9) 1 (6)
CNS, central nervous system; EGFR, epidermal growth factor receptor.
FIGURE 1.  Time to treatment failure.
FIGURE 2.  Response rates in the patient group with central 
nervous system metastasis on afatinib.
FIGURE 3.  Patterns of response to afatinib in the patient 
group with central nervous system metastasis.
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and a cerebral metastasectomy, he received four cycles of 
cisplatin (40 mg/m2 d1+8)/vinorelbine (25 mg/m2 d1+8)/bev-
acizumab (15 mg/kg d1, q d29) and bevacizumab was con-
tinued up to June 2008. In January 2009, a bone metastasis 
was resected and irradiated (30 Gy) and a radiation of the 
brain was performed (30 Gy) followed by a second-line ther-
apy with erlotinib. In March 2012, a metastasectomy of the 
right adrenal gland was performed with confirmation of an 
EGFR-wildtype in the resection specimen. One month later, 
the patient developed new cerebral and pulmonal metastases 
and third-line therapy with afatinib (50 mg/day) was initi-
ated. The trough plasma concentration 7 weeks after the start 
of afatinib was 35.6 ng/ml; 3 hours after administration, it 
was 59.07 ng/ml BIBW 2992 BS. The patient experienced a 
partial response with little side effects (grade 1: diarrhea and 
rash). In January 2013, the dosage of afatinib was increased 
to 60 mg/day and in April 2013 to 70 mg/day at the discretion 
of the treating physician. In October 2013, after 16 months 
of treatment with afatinib, the patient died due to rapid tumor 
progression.
DISCUSSION
Heavily pretreated NSCLC patients with CNS metasta-
ses who progressed on erlotinib or gefitinib seemed to respond 
well to treatment with afatinib during a CUP. The rates of both 
systemic and CNS disease control were high. These results are 
encouraging, as CNS metastases negatively impact the quality 
of life and OS of many patients with NSCLC and continue to 
present a therapeutic challenge.36,37 In addition to the thera-
peutic effect of afatinib, the relatively long OS of patients with 
CNS metastases in the CUP may also reflect the prognostic 
relevance of EGFR mutations and a degree of preselection for 
patient motivation and general state of health.
Systemic chemotherapy is often ineffective in patients 
with CNS metastases, perhaps due to poor permeability of 
the blood–brain barrier to these agents.25,26 The cerebral effi-
cacy of TKIs seems to be somewhat higher, and response rates 
of 75 to 89% in EGFR-mutated NSCLC patients with CNS 
metastases treated with EGFR-TKIs have been reported.38
A sequential approach to treatment in which patients 
with EGFR-mutated NSCLC and CNS metastases are 
offered a trial of TKI treatment, and brain irradiation is 
delayed until clinical or radiological progression occurs, 
may be reasonable,39,40 and could delay or prevent patient 
exposure to the side effects of cranial irradiation.41 However, 
in addition to evidence that TKIs are effective in patients 
with brain metastases, there is evidence that patients treated 
with EGFR-TKIs or anaplastic lymphoma kinase-TKIs over 
a period of many months may have an increased risk of 
developing CNS metastases.42 It may be that the concen-
tration of TKI in the CSF is sufficient to inhibit treatment-
naive, non–TKI-resistant cells, but that over time the lower 
drug concentrations select for resistant clones.
Due to its potency at relatively low concentrations, afa-
tinib may remain effective in the CSF after resistance to other 
TKIs has developed. In preclinical studies, afatinib dem-
onstrated high potency of kinase inhibition against EGFR, 
HER2, and ErbB4 kinases with 50% inhibitory concentration 
(IC
50
) of 0.5, 14, and 1 nM, respectively.15,16,43 The median 
inhibitory concentration of afatinib (in vitro) is lower than 
that of currently available EGFR-TKIs (Table 3).15,44 This 
suggests that afatinib has the potential to treat CNS metasta-
ses effectively, despite incomplete penetration of the blood–
brain barrier. The regression of CNS metastases observed 
during the afatinib CUP provides clinical evidence that afa-
tinib concentration in the CSF is sufficient to inhibit tumor 
growth. Subgroup analyses of the LUX-Lung trials have 
also documented the effectiveness of first-line afatinib in the 
treatment of CNS metastases in EGFR-mutated NSCLC,45 
and support the observations within the afatinib CUP. TTF 
in the CUP did not differ in patients with and without CNS 
metastases. Over 70% of the patients with CNS metastases 
had either PR or SD and 76% of the patients developed no 
new metastases.
Therapy with erlotinib results in penetration into the 
CSF previously reported to range from 2.5% to 13%; and 
gefitinib concentration in the CSF has been reported to reach 
approximately 1% of serum levels.36,46,47 Very little is known 
about the ability of afatinib to penetrate into the CSF. The 
TABLE 3.  IC50 Values of Reversible EGFR-TKIs and Afatinib
EGFR Wildtype EGFR L858R EGFR Exon 19 Deletion
LoVo A431 H2073 H3255 H1975 EGFR T790M PC-9 PC-9/VanR EGFR T790M
Afatinib 15 33 25 0.9 22 0.6 3
Gefitinib 59 73 61 11 3100 7 740
Erlotinib 91 250 110 9 6100 6 1300
Excerpt from Cross et al.44
FIGURE 4.  Pharmacokinetic and clinical data from 
case report 1. CSF, cerebrospinal fluid; KPS, Karnofsky 
 performance status.
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plasma and CSF concentrations of afatinib were measured in 
one patient in the CUP (see Case Report 1) and gave a CSF to 
plasma ratio of below 1%. Calculating the molar concentra-
tion would lead to a value of 0.95 nM, which is around the IC
50
 
value for EGFR/ErbB1 (0.5 nM) and for HER4/ErbB4 (1 nM) 
but below the value for HER2 (14 nM).
The effective concentration of afatinib in CSF has not 
been described previously. Nevertheless, the correlation with 
dramatic clinical improvement and disappearance of tumor 
cells in the CSF suggests that the dose reached was sufficient 
to inhibit tumor growth. One could speculate that there are 
distribution processes in the CNS which could lead to higher 
concentrations at the target tissue. Afatinib has a high affinity 
to EGFR, which should be overexpressed in the tumor tissue 
and, thus, could be enriched there. It should also be consid-
ered that the protein content of CSF is much lower than that 
of blood, so ratios of the free (effective) concentrations would 
probably be higher.
By comparison, erlotinib levels in the CSF at approxi-
mately 5% of the plasma levels have been reported to be suf-
ficient to inhibit the receptor, whereas gefitinib levels in the 
CSF (approximately 1% of plasma levels) have been reported 
to be insufficient for inhibition.36 The concentration of afa-
tinib in the cerebrospinal fluid is nearly 1 nMol. Clearly some 
afatinib penetrates into the CNS, and achieves concentrations 
high enough to have a clinical effect. Dose modifications of 
afatinib based on individual tolerability reduced excessive 
afatinib plasma levels (as in case report 1), whereas experi-
mental escalation up to 70 mg from an initial dose of 50 mg 
in case report 2 prolonged response. Case report 2 involved a 
trial of high-dose afatinib to treat progressing brain metasta-
ses. The patient remained on high-dose (70 mg/day) afatinib 
for 6 months. Cases involving the use of high-dose or pulsed 
EGFR-TKIs for the treatment of progressive brain metastases 
have been reported in the literature.48–50 Hata et al.50 gave erlo-
tinib at a dose of 300 mg on alternating days and Dhruva and 
Socinski.49 gave 600 mg every 4 days. A case series involv-
ing 10 patients treated with pulsed erlotinib 1000 to 1500 mg 
once weekly was presented at the 2013 American Society of 
Clinical Oncology meeting but has to our knowledge not yet 
been published.48,51 The responses seen in these patients sug-
gest that the efficacy of these TKIs in the brain may be limited 
by insufficient penetration of the drugs into the CSF and may 
be increased by increasing the dose. However, as clinical trial 
data supporting the use of these strategies is not yet available, 
the use of high-dose or pulsed TKIs should be considered 
experimental at this time.
In summary, heavily pretreated patients with EGFR-
resistant NSCLC and CNS metastases benefited from 
treatment with afatinib in this CUP. In light of the lack of 
established treatment options in this setting, these results are 
particularly encouraging.
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APPENDIx. THE AFATINIB COMPASSIONATE 
USE CONSORTIUM (ACUC) STUDy GROUP 
MEMBERS
The study group members are A. Abdollahi, A. Ammon, 
S.P. Aries, C. Arntzen, H.J. Achenbach, D. Atanackovic, 
A. Atmaca, N. Basara, D. Binder, B. Borchard, M. Bos, W. 
Brugger, S. Budweiser, K. Conrad, K. Corduan, D. Cortes-
Incio, B. Dallmeier, C. Denzlinger, H.G. Derigs, N. Dickgreber, 
I. Dittrich, T. Düll, W. Engel-Riedel, M. Faehling, A. Fertl, 
J.R. Fischer, D. Fleckenstein, G. Folprecht, A. Forstbauer, 
Y. France, N. Frickhofen, S. Frühauf, M. Gardizi, T. Gauler, 
C. Gessner, W. Gleiber, E. Gökkurt, M. Görner, C. Grah, J. 
Greeve, J. Greiner, F. Griesinger, C. Grohé, W. Grüning, D. 
Guggenberger, S. Gütz, C. Hannig, D. Heigener, M. Heilmann, 
B. Heinrich, G. Hense, M. Hoiczyk, R.M. Huber, G. Illerhaus, 
G. Jacobs, P. Jung, K.O. Kambartel, L. Kayikci, J. Kern, J. 
Kersten, M. Kiehl, M. Kimmich, J. Kisro, H. Knipp, Y.D. Ko, 
J.U. Koch, C.H. Koehne, J. Kollmeier, A. Kommer, W. Körber, 
K. Kratz-Albers, G. Krause, R. Krügel, E. Laack, R. Leistner, U. 
Liebers, M. Lommatzsch, C. Maintz, C. Mozek, A. Matzdorff, 
M. Mohr, W. Neumeister, H. Nolte, T. Overbeck, M. Östreicher, 
J. Panse, T. Pelzer, K. Peters, M. Planker, A. Reissig, M. Ritter, 
A. Rittmeyer, S. Rösel, P. Sadjadian, B. Sandritter, M. Schatz, 
M. Scheffler, G. Schmid-Bindert, A. Schmittel, C.P. Schneider, 
W. Schneider-Kappus, F. Schneller, E. Schorb, J. Schreiber, 
F. Schüler, M. Schuler, A. Schulz-Abelius, C. Schumann, W. 
Schütte, S. Schütz, M. Schütz, M. Sebastian, M. Serke, D. 
Spissinger, W. Spengler, H. Staiger, U. Steffen, I. Stehle, H. 
Steiniger, K. Stengele, S. Steppert, J. Stöhlmacher-Williams, T. 
Strapatsas, B. Sulzbach, A. Tessmer, M. Thomas, B. Thöming, 
D. Ukena, B. Wagner, T. Wagner, D. Wagner-Hug, H. Wahn, T. 
Wehler, R. Wiewrodt, C. Witt, M. Wohlleber, J. Wolf, M. Wolf, 
K. Wricke, O. Zaba, and I. Zander.
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